Ewing Sarcoma

In conclusion, EWSAT1 promotes the malignant phenotypes of CRC cells by regulating the miR-330-5p/CPEB4 axis. This molecular axis may provide new insights into the mechanisms of CRC progression and potential targeted interventions.

CYP26A1 expression was most frequent in giant cell tumors of bone. While also detected in a subset of other bone tumors, expression was limited or absent in most benign and malignant lesions, and entirely absent in normal bone tissue. These findings provide novel descriptive insight into CYP26A1 distribution and support further investigation into its role in retinoid-related pathways in bone tumor biology.

P2, N=73, Recruiting, Northwestern University | N=29 --> 73 | Trial completion date: Jul 2029 --> Jul 2033

Consequently, the direct in vivo evidence for the role of NPY in metastasis and clinical data associating the expression of NPY and its receptor with adverse disease phenotypes are growing. Understanding the mechanisms underlying these effects may lead to the design of novel therapeutic approaches targeting the NPY system to prevent cancer progression.

The results of the screen revealed that a PI3K inhibitor, copanlisib, combined with a CDK4/6 inhibitor, ribociclib, exhibited strong synergistic anti-Ewing sarcoma activity. In two xenograft models of Ewing sarcoma, we demonstrated that the combination significantly prolonged survival compared to treatment with either vehicle or single-agent therapy alone. Our findings identify a new candidate therapy combination for Ewing sarcoma and provide a resource of additional potential synergistic combinations for future validation.

Our findings establish that integrin CD11b/CD18 orchestrates antitumor immunity by modulating the TME, particularly through direct TAM reprogramming and indirect TAN-TAM crosstalk, highlighting its potential as an immunotherapeutic target for CAC.

P1/2, N=20, Recruiting, Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2023 --> Dec 2029 | Trial primary completion date: May 2023 --> May 2029

Here, we describe two patients with EWSR1::PATZ1 sarcoma, of which one patient was initially misdiagnosed as synovial sarcoma and RMS on two occasions. These patients underscore the diagnostic challenges and therapeutic uncertainties surrounding EWSR1::PATZ1 fusion sarcomas, emphasizing the need for further large collaborative studies to establish optimal prognostic implications and management strategies for this rare entity.

Key findings were validated by CETSA, isothermal dose-response fingerprinting, co-immunoprecipitation, and ubiquitination assays. These results demonstrate that shogaol exerts dual cytotoxic effects through the PLK1/NPM1 axis, presenting a potential natural therapeutic approach for Ewing sarcoma.

These findings offer mechanistic insights for the rational design of next-generation IGF-1R inhibitors, suggesting that optimal candidates should integrate a hydrophobic core for engagement of the inactive state with strategically positioned polar or ionizable groups to effectively interact with the more electrostatically enriched active conformation. The online version contains supplementary material available at 10.1007/s40203-026-00668-7.

Our studies revealed DBD-α4 helix is crucial for cooperative binding of EWSR1::FLI1 at GGAA microsatellites. This binding underlies many aspects of genome regulation by EWSR1::FLI1, such as formation of topologically associated domains (TADs), chromatin loops, enhancers, and productive transcription hubs.

This case highlights the diagnostic challenges of primary intracranial Ewing-like sarcoma and its potential to present with severe and irreversible visual impairment. Early neuroimaging in patients with persistent seizures is essential to avoid diagnostic delay, and molecular confirmation remains crucial for future cases.